Detalhe da pesquisa
1.
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Cancer Chemother Pharmacol
; 89(1): 93-103, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34750637
2.
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
J Clin Oncol
; 38(15): 1693-1701, 2020 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32208957
3.
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Clin Cancer Res
; 14(21): 7110-5, 2008 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18981010
4.
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Cancer Chemother Pharmacol
; 78(3): 491-500, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-27392790
5.
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 76(3): 587-95, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26210682
6.
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 68(6): 1565-73, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21547572